This study will examine whether dark chocolate affects the way patients with hypertension (high blood pressure) respond to insulin, a hormone secreted by the pancreas that regulates blood glucose (sugar) levels. In many people with hypertension, insulin is not as effective in helping the body use glucose. This is called insulin resistance. Insulin also increases blood flow into muscle by opening inactive blood vessels. Laboratory studies suggest that eating dark chocolate may improve blood pressure. This study will determine whether dark chocolate improves insulin resistance or changes how blood vessels react to insulin in hypertensive people.

People between 21 and 60 years of age who have high blood pressure and are not pregnant may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests.

Participants refrain from eating foods containing chocolate or cocoa for 1 week and then come to the clinic on three separate occasions 3 weeks apart for a glucose clamp test and contrast ultrasound, described below. After the first glucose clamp test is completed, subjects are randomly assigned to eat either a dark chocolate or placebo bar once a day for 2 weeks. At the end of the 2 weeks, they return for a second glucose clamp test. After the second test is finished, they stop taking the bar for 1 week and then start again for another 2 weeks. For this 2-week period, those who were given the chocolate bar the last time take placebo this time, and those who took placebo now take chocolate. After 2 weeks of taking chocolate or placebo, they then take the third and last glucose clamp test.

Glucose clamp test: This test measures how the body responds to insulin. Subjects fast the night before each test and do not eat until the test is over, usually in the early afternoon. For the test, the subject lies in a bed or reclines in a chair. A needle is placed in a vein in each arm - one for collecting blood samples and the other for infusing glucose, insulin, and a potassium solution. Blood glucose and insulin levels are measured frequently during the test and the rate of the glucose infusion is adjusted to keep blood glucose at the baseline (fasting) level. Blood samples are tested for blood count, electrolytes, liver function, insulin, lipids, and other substances, in addition to glucose levels. The test takes about 4 hours. After the test, blood glucose levels are monitored for another 2 hours, and during this time, subjects eat a meal.

Contrast ultrasound: This test uses a contrast agent to measure blood flow in the brachial artery of the arm to assess how many capillaries (very small blood vessels) are being used to supply nutrients and oxygen to the muscle. One of the catheters placed in the arm for the glucose clamp test is used to infuse a microbubble contrast agent (gas-filled bubbles the size of red blood cells). The bubbles stay in the blood vessel and create a signal in response to ultrasound that helps give information about the distribution of capillaries in the forearm. The bubbles are infused once at the beginning of the glucose clamp test and again 2 hours later.

In addition to the above procedures, patients come to the clinic every Monday, Wednesday, and Friday during the 6-week study to have their blood pressure measured.

Condition	Treatment or Intervention	Phase
Hypertension	Behavior: Effects of dark chocolate	Phase I

Further Study Details: 

Expected Total Enrollment:  30

Dark chocolate and other cocoa products contain antioxidants including epicatechin that have beneficial effects on vascular function. Oral consumption of dark chocolate lowers blood pressure in elderly subjects with isolated systolic hypertension while drinking cocoa acutely improves flow-mediated vasodilation in subjects with cardiovascular risk factors. Work from our lab and elsewhere has shown that regulation of hemodynamic and metabolic homeostasis are coupled such that subjects with essential hypertension are also insulin resistant. Therefore, we hypothesize that dark chocolate consumption will improve both blood pressure and insulin sensitivity in subjects with essential hypertension. To test this hypothesis, we will conduct a randomized double-blind, crossover study in subjects with essential hypertension to evaluate the effects of dark chocolate versus placebo on blood pressure, insulin sensitivity, and insulin-mediated capillary recruitment in skeletal muscle. After a 7 day cocoa-free run-in period, subjects will be randomized to receive 15 consecutive daily doses of either dark chocolate (100 g, containing 500 mg of polyphenols and 562 kcal) or placebo (polyphenol free, 562 kcal). After the 15 day treatment period, the subjects will enter a 1 week cocoa-free washout period followed by cross-over to the other treatment. Subjects will be counseled to maintain an isocaloric diet during the study. Blood pressure, insulin sensitivity, and insulin-mediated capillary recruitment will be assessed in each subject after the run-in period, after 15 days of treatment, and after completion of the cross-over. Blood pressure will also be measured every Monday, Wednesday, and Friday for the duration of the study. Insulin sensitivity will be measured using the hyperinsulinemic euglycemic glucose clamp technique. Insulin-stimulated capillary recruitment in forearm skeletal muscle will be measured by ultrasound with "microbubble" contrast during the glucose clamp studies. Peak and trough plasma epicatechin levels will be measured prior to each glucose clamp study using an HPLC assay. This study will determine if short-term oral administration of dark chocolate is effective at lowering blood pressure, improving insulin sensitivity, and restoring vascular function in subjects with essential hypertension. This is highly relevant to major public health problems such as diabetes, obesity, hypertension, and cardiovascular diseases where insulin resistance and vascular dysfunction are important pathophysiological components.

Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA
Hypertensive subjects between the ages of 21 - 60 years in good general health except for mild to moderate hypertension (blood pressure between 140/95 and 170/110 off medication), on no medication or nutritional supplements except for antihypertensive agents. Subjects will be taken off all antihypertensive drugs for one week prior to study and for the duration of the study. During the time subjects receive no antihypertensive therapy, their blood pressure will be monitored at least daily (either at home, in the clinic, or at another convenient facility). If a subject's blood pressure exceeds 170/110 on three determinations over a period of at least 15 minutes, the subject will be withdrawn from the study and appropriate antihypertensive therapy resumed. In addition, if the subject's blood pressure exceeds 160/100 during measurements on three consecutive days, the subject will be withdrawn from the study and appropriate antihypertensive therapy resumed.
EXCLUSION CRITERIA
Subjects will be excluded if they have diabetes, pregnancy, liver disease, pulmonary disease, renal insufficiency, coronary heart disease, heart failure, peripheral vascular disease, coagulopathy, actively smoked tobacco within last two years, in treatment for any form of cancer, positive tests for HIV, hepatitis B or C, or take systemic corticosteroids. These conditions are all known to adversely influence insulin sensitivity.
Subjects will be excluded if they have a history of malignant hypertension, aortic aneurysm or stroke.
Subjects with known hypersensitivity to octafluoropropane or with known cardiac shunts will also be excluded from participating because of potential adverse effects from microbubble contrast agent.
Subjects will be excluded if they are unable to give informed consent for all procedures.
Children are excluded from this study because children are not typically hypertensive.

Maryland
      National Center for Complementary and Alternative Medicine (NCCAM), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States; Recruiting

Study ID Numbers:  050047; 05-AT-0047
Record last reviewed:  November 24, 2004
Last Updated:  February 11, 2005
Record first received:  December 14, 2004
ClinicalTrials.gov Identifier:  NCT00099476
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08